Compare WST & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | TCOM |
|---|---|---|
| Founded | 1923 | 1999 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 29.3B |
| IPO Year | 2004 | 2003 |
| Metric | WST | TCOM |
|---|---|---|
| Price | $346.61 | $44.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $325.86 | $78.75 |
| AVG Volume (30 Days) | 640.3K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-18-2026 |
| Dividend Yield | 0.30% | ★ 0.57% |
| EPS Growth | ★ 1.49 | N/A |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $2,886,900,000.00 | N/A |
| Revenue This Year | $6.76 | $15.73 |
| Revenue Next Year | $6.22 | $13.00 |
| P/E Ratio | $85.87 | ★ $9.06 |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $223.83 | $38.04 |
| 52 Week High | $386.00 | $79.00 |
| Indicator | WST | TCOM |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 47.75 |
| Support Level | $349.41 | $38.04 |
| Resistance Level | $358.67 | $47.48 |
| Average True Range (ATR) | 6.59 | 0.84 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 70.98 | 18.11 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.